HOUSTON INNOVATORS PODCAST EPISODE 74

Houston startup plans to expand to revolutionize tech-enabled small business support

WizeHire CEO Sid Upadhyay joins the Houston Innovators Podcast to share his big plans for his company as it gears up for growth. Photo courtesy of WizeHire

Hiring and recruiting has been a challenging and inefficient process for small businesses — yet it could not be more important as a company with a small, growing team.

"Today, whether you're running a startup for the first or second time, at the end of the day, you're just wearing too many hats," says Sid Upadhyay, co-founder and CEO of WizeHire, on this week's episode of the Houston Innovators Podcast. "Recruiting is one of those things where we know talent is the lifeblood of our businesses, but we just don't have the time to think about the process."

Upadhyay says his company, Houston-based WizeHire, lives and breathes for small businesses, and in 2014 the company launched to tap into technology to provide a software service that can streamline a more effective way for startups and small businesses to hire — and hire optimally.

Last month, the company — founded by Upadhyay, Nick Carneiro, and Jay Niblick — closed a $7.5 million series A funding round that was led by Houston-based Mercury Fund and Amplo, which is based just north of Houston in Spring. Additional support came from existing backers Ruchit Shah and RigUp co-founder Sandeep Jain. The fresh funding will go toward expansion — both of its team as well as WizeHire's products.

Upadhyay says the the effects of the pandemic — which includes many businesses ceasing to hire — had profound repercussions on WizeHire.

"We saw half our revenue disappear overnight," Upadhyay says. "As we were going through that up-and-down roller coaster, it was one of the most humbling experience."

Upadhyay says WizeHire has a close relationship with its customers, and they were reaching out asking for guidance from WizeHire during the uncertain times. Upadhyay's team took the opportunity to provide low or no-cost support, especially when it comes to navigating the CARES Act.

"We started to educate our customers about everything from PPP loans to tax credits," Upadhyay says. "We went so far as to connect 300 of our customers to banks — otherwise they wouldn't have been able to get these loans."

These efforts are what led WizeHire to its first venture capital raise. The bootstrapped company has a client base that includes more than 7,000 businesses, and the company recorded $4.7 million in run rate in 2020. Now, in light of the impact WizeHire was able to make with its clients during the pandemic, Upadhyay says the company is going to expand to include other key services, like identifying tax credits.

"We're really going beyond just the hire," Upadhyay says. "We're getting to this role where we're going to help you grow your business."

Upadhyay discusses more about WizeHire's plans for 2021 and the intentionality of the business on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News